Late-breaking abstract added to the program
GS2-12 AFT-38 PATINA: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor-Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Otto Metzger, Dana-Farber Cancer Institute, Harvard Medical School, Alliance for Clinical Trials in Oncology Boston, Massachusetts
Dr. Metzger will present this phase III trial during the General Session on Thursday morning.
luding late-breaking abstracts. Note: the PDF is a large file containing more than 3,000 pages.
Access and download the report
Access embargoed abstracts as they are released
Check back here on Wednesday, Thursday, and Friday as embargoed abstracts are released (click title for full abstract)
Wednesday
GS1-01: Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy & Combined with Abemaciclib, for Patients with ER+, HER2- Advanced Breast Cancer (ABC), Pretreated with Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial
Presenting Author(s): Komal Jhaveri
Read the press release
GS1-06: PRO B - a superiority randomized controlled trial evaluating the effects of symptom monitoring in metastatic breast cancer patients
Presenting Author(s): Maria Margarete Karsten
GS1-08: Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study
Presenting Author(s): Matteo Lambertini
Read the press release
GS1-09: OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer: longerterm follow
Presenting Author(s): Judy Garber
Read the press release
PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
Presenting Author(s): Cristina Saura
Thursday
GS2-02: Impact of Tamoxifen Only after Breast Conservation Surgery for "Good Risk" Duct Carcinoma in Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial
Presenting Author(s): Jean Wright
GS2-03: Does postmastectomy radiotherapy in 'intermediate-risk' breast cancer impact overall survival? 10 year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators
Presenting Author(s): Ian Kunkler
GS2-05: Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25)
Presenting Author(s): Eun-Sil Hwang
GS2-06: Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25)
Presenting Author(s): Ann Partridge
Friday
GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy
Presenting Author(s): Nicholas Turner
GS3-03: Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer
Presenting Author(s): Nan Chen
GS3-09: Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer.
Presenting Author(s): Pedram Razavi
Complete abstracts now online
Full Abstracts for SABCS® 2024 are now available.
On-site Eposter access
Eposters will be available for in-person viewing at SABCS 2024. Go to Booth #1433 in the Exhibit Hall, Halls 2-3, to view them live during the symposium.
Abstract submission is now closed for SABCS® 2024
Register to attend what promises to be the largest and most expansive SABCS® in history this December in San Antonio.
If you need to, you can log back into the abstract portal to view your information, but please note you can no longer make changes to your abstract.
Also, you can access abstract titles and presentation times on the Full Program. Then you can plan your personal agenda for four days of education, networking and the sharing of state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease at SABCS® 2024!
SABCS® 2024 Scientific Session Abstract Title and Text Release and Embargo Policy
The abstract title and text release schedule is as follows:
- Regular and Late-Breaking Abstract titles will be published on our website as part of the program agenda at 4:30 p.m. CT on Friday, November 1, 2024.
- Regular and Late-Breaking Abstract text will be published at 4:30 p.m. CT on Monday, November 25, 2024.
- The submitting author will be notified if your abstract is selected to the official SABCS® press program. Apart from those selected for the press program, abstracts submitted to SABCS® are confidential and embargoed until they are published on the SABCS® website November 25, 2024. Embargoes on abstracts lift as soon as the abstracts are available online. To extend the Embargo to the start of your scheduled session email sabcs@uthscsa.edu.
- For more information on the press embargo policy please check out our Media web page.
Once an abstract is accepted for presentation, SABCS holds the copyright to the abstract.
Scientific session embargo requests
Any request for scientific session embargo not related to press or media should be sent to sabcs@uthscsa.edu by Monday, October 7.
Questions? Contact the symposium office at sabcs@uthscsa.edu or 210-450-1550.
Confirmation of No Prior Publication/Presentation
Authors who submit an abstract confirm they have not previously published these data, they have not previously presented them at another scientific meeting, and that they are not planning to present or publish them prior to the dates of the SABCS® 2024. Preprints (draft research papers posted online before peer review) are not considered to be a prior publication if they are posted online before abstracts are submitted SABCS®.
Abstracts submitted to SABCS® are confidential and embargoed until SABCS® publishes the abstracts.
Certain laws may require disclosure of clinical trial data through federal and international registries within a specific amount of time following trial completion, or disclosure of clinical trial data by federal and international agencies for regulatory purposes related to drug safety and efficacy. Such disclosures will not be considered a violation of the SABCS’s Embargo Policy, but the courtesy of advance notice to the SABCS® by email at sabcs@uthscsa.edu is requested.
Any other exceptions to this policy are at the discretion of SABCS® leadership.
Lobular Breast Cancer Research Abstract Merit Award
The Lobular Breast Cancer Alliance (LBCA) is excited to announce a new $5,000 sponsorship - the Lobular Breast Cancer Research Abstract Merit Award, in collaboration with the American Association for Cancer Research (AACR). This merit award will recognize the best abstracts focusing on lobular breast cancer research among those selected for poster presentation at the 47th Annual San Antonio Breast Cancer Symposium (SABCS®) held December 10-13, 2024, at the Henry B. Gonzalez Convention Center in San Antonio, TX.
Award submissions are no longer being accepted.
FAQS
What types of studies are considered for late-breaking abstracts?
- Abstracts detailing highly significant and timely findings in any area of breast cancer research, including clinical trials, that were not available at the time of the regular abstract deadline will be considered for presentation at the 2024 SABCS. Only those abstracts that are deemed to be of high scientific priority will be accepted.
May I present more than one abstract?
- There is no limit to the number of abstracts an author can submit and present, however authors are limited to one oral presentation at the SABCS®.
How many authors can be listed on an abstract?
- There is 50 author limit per abstract.
When will I find out if my abstract has been accepted for presentation?
- Late September/Early October 2024: Decision Letters and Presentation Instructions will be emailed to the Presenting Author.
If my abstract is accepted, what is the presentation format?
- Authors who are selected as the presenter of an abstract (at the time of submission) will be provided with instructions regarding the type of presentation to be made and the date and time of the presentation. For abstracts selected to be presented as posters, the SABCS will provide poster numbers and pushpins. For abstracts that are selected for short talks, slides must in 16:9 format and developed in PowerPoint.
Are there poster printing services available?
- Poster printing services are available for the SABCS®. Please continue to monitor our website for more information.
How do I reference an abstract in the conference proceedings?
- Abstracts that are printed in the SABCS® conference proceedings should be referenced as follows:
Author(s) of abstract.Title of abstract [abstract]. In: Name of conference or title of publication; conference dates; place of conference. place of publication: publisher; date of publication and abstract number.
Example:
Li TW, Jones PA. Methylation changes in early embryonic genes in cancer [abstract]. In: Proceedings of the 2024 San Antonio Breast Cancer Symposium; 2024 Dec 10-13; San Antonio, TX.; 2024. Abstract nr 30.
Since I transferred copyright to SABCS® when I submitted my abstract for publication in a conference Proceedings, can I re-use the text of my abstract that I submitted?
- Authors may reproduce the abstract - including tables - without requesting additional permission for the following:
- In books, reviews, or subsequent research articles they write
- To post a link to the online version of the abstract on their institutional website, if required by their institution
- To submit a copy of their article to their university in support of a doctoral thesis.
- For all other purposes you must contact sabcs@uthscsa.edu to request permission to reuse the text of the abstract.